#Neurological | #Sleep | #Stress

DSIP (Delta Sleep-Inducing Peptide) — Research Overview (RUO)

A comprehensive technical summary of the nonapeptide DSIP, originally isolated for its hypnogenic properties and subsequently investigated for its complex role in stress resilience, circadian regulation, and neuroendocrine signaling.

Peptide Name:

DSIP (Delta Sleep-Inducing Peptide)

Type:

Endogenous Nonapeptide

Sequence Length:

9 Amino Acids

CAS Number:

62568-57-4

Primary Research Focus:

Sleep Architecture & Stress Response

Discovery:

1974 (Schoenenberger & Monnier)

Molecular Formula:

C₄₇H₆₇N₁₁O₁₃

Molecular Weight:

~849.9 Da

Amino Acid Sequence:

Trp–Ala–Gly–Gly–Asp–Ala–Ser–Gly–Glu

Structure Note:

DSIP is predominantly found in free form but may also circulate bound to carrier proteins in plasma. The peptide is highly hydrophilic.

Store powder at +4°C (short term) or -20°C (long term). Keep desiccated.

For laboratory research use only. Reconstitute using sterile bacteriostatic water consistent with established laboratory research protocols. Preparation should be performed under aseptic conditions. Reconstituted material is not intended for long-term storage.

Amino Acid Sequence:

Sleep Architecture & Circadian Research

Initial studies in 1974 identified DSIP’s ability to enhance delta (slow-wave) EEG activity in rabbits. Subsequent investigations across multiple species (rats, cats, humans) produced heterogeneous results.

Reviews of the literature (e.g., Kovalzon, 1994) indicate DSIP does not act as a classic sedative or hypnotic agent. Its effects appear highly dependent on baseline physiological state and circadian timing. DSIP is hypothesized to function as a sleep-promoting modulator rather than a direct inducer, potentially via circadian pacemaker modulation.

Research suggests DSIP may stabilize sleep architecture in subjects with disturbed sleep patterns rather than extend sleep duration in healthy, rested subjects.

Stress Response & Neuroendocrine Signaling

A substantial body of research categorizes DSIP as a stress-limiting peptide. In rodent models of acute stress, DSIP administration has been observed to:

Reduce stress-induced elevations of Corticotropin-Releasing Hormone (CRH) and ACTH
Modulate Monoamine Oxidase Type-A (MAO-A) activity, influencing serotonin and catecholamine metabolism
Normalize physiological stress markers such as blood pressure and heart-rate variability

These findings suggest a regulatory role within the Hypothalamic-Pituitary-Adrenal (HPA) axis, acting as a buffer against excessive stress responses.

CNS Signaling & Neurotransmitters

GABAergic & Glutamatergic Systems Evidence suggests DSIP may modulate the balance between excitatory (glutamate) and inhibitory (GABA) neurotransmission. By influencing GABAergic tone, DSIP may contribute to anxiolytic-like effects observed in behavioral assays.

Opioid Interactions Some studies indicate potential interaction with endogenous opioid pathways. Naloxone (an opioid antagonist) has been shown to block certain DSIP-mediated effects in experimental settings, suggesting a multi-pathway mechanism.

Mitochondrial Function & Metabolic Resilience

Exploratory research has investigated DSIP’s role in oxidative phosphorylation. In hypoxia and oxidative stress models, DSIP has been studied for its ability to:

Preserve mitochondrial membrane integrity
Maintain efficiency of the electron transport chain
Reduce accumulation of reactive oxygen species (ROS)

These effects suggest a potential role in cellular stress resilience.

Research Limitations

Short Half-Life: Native DSIP has a plasma half-life measured in minutes, rapidly degrading via aminopeptidases, complicating in-vivo research
Inconsistent Reproducibility: Outcomes vary with circadian timing and baseline stress levels, leading to conflicting results across studies
Mechanism Ambiguity: No high-affinity DSIP-specific receptor has been conclusively identified; effects likely arise from indirect modulation of NMDA, GABA, and other systems

Key Scientific References

Schoenenberger, G. A., & Monnier, M. (1977). Characterization of a delta-electroencephalogram (sleep)-inducing peptide. PNAS, 74(3), 1282-1286.
Kovalzon, V. M. (1994). DSIP: behavioral effects. Behavioural Brain Research (Review).
Graf, M. V., & Kastin, A. J. (1986). Delta-sleep-inducing peptide (DSIP): an update. Peptides, 7(6), 1165-1187.
Sudakov, K. V., et al. (2008). DSIP peptide as a factor increasing resistance of animals to emotional stress. Neuroscience and Behavioral Physiology.

The compound listed below is referenced in research contexts related to the mechanisms discussed in this article.

The compound DSIP discussed on this page is a chemical standard intended strictly for in-vitro and laboratory research applications (e.g., neuroscience signaling assays, sleep architecture models). It is not a drug, dietary supplement, or food additive. It is not intended for human consumption, injection, or therapeutic use. All handling must be performed by qualified professionals in a laboratory setting.

DSIP (Delta Sleep-Inducing Peptide) — Research Overview (RUO)

Peptide Name:

Type:

Sequence Length:

CAS Number:

Primary Research Focus:

Discovery:

Molecular Formula:

Molecular Weight:

Amino Acid Sequence:

Structure Note:

Amino Acid Sequence:

Age Verification Required

Epithalon

DSIP

CJC-1295 No DAC / Ipamorelin

Cagrilintide

BPC-157

AOD-9604